Literature DB >> 17185803

Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature.

Cihangir Erem1, Halil Onder Ersöz, Kubilay Ukinç, Avni Murat Avunduk, Arif Hacihasanoglu, Mustafa Koçak.   

Abstract

Carbohydrate intolerance is a common feature of acromegaly. Frank diabetes mellitus is seen in about 10-20% of patients. There is no report of acromegaly presenting with diabetic ketoacidosis (DKA), associated with retinitis pigmentosa (RP), in the literature. We report the occurrence of DKA and RP in a patient with acromegaly. A 39-year-old Turkish man was admitted to the emergency ward with a 1-mo history of thirst, polyuria, weight loss of 10 kg, and loss of consciousness for 2 d. Physical examination revealed findings suggestive of acromegaly, including coarse facial features and enlargement of his hands and feet. At ophthalmological examination, funduscopy showed RP. Laboratory studies confirmed the diagnoses of DKA and acromegaly. Magnetic resonance imaging disclosed the presence of a pituitary adenoma. During the medical treatment with octreotide, symptomatic sinusoidal bradycardia was developed (pulse rate 45 bpm, and blood pressure 70/40 mmHg). Octreotide therapy was stopped. Pituitary adenoma was removed surgically. For treatment of DKA, insulin need was very high in the first days after the onset of ketoacidosis, but decreased after initiation of treatment with octreotide and after successful operation. Insulin was stopped 7 d after surgery. Follow-up showed normalization of growth hormone levels and plasma glucose levels. Only six other cases of DKA associated with acromegaly and only three other cases of RP associated with acromegaly were found in the medical literature. In conclusion, to our knowledge, the present case is a first report of DKA and RP in patient with acromegaly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185803     DOI: 10.1385/ENDO:30:1:145

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

1.  AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly.

Authors:  David M Cook; Shereen Ezzat; Laurence Katznelson; David L Kleinberg; Edward R Laws; Todd B Nippoldt; Brooke Swearingen; Mary Lee Vance
Journal:  Endocr Pract       Date:  2004 May-Jun       Impact factor: 3.443

2.  Effect of octreotide pretreatment on surgical outcome in acromegaly.

Authors:  A Colao; D Ferone; P Cappabianca; M L del Basso De Caro; P Marzullo; A Monticelli; A Alfieri; B Merola; A Calì; E de Divitiis; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

3.  Death from diabetic ketoacidosis after cessation of octreotide in acromegaly.

Authors:  M J Abrahamson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

4.  Thyroid disease and retinitis pigmentosa.

Authors:  G Proto; S Bacchetti; F Bertolissi
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

5.  Diabetic ketoacidosis in a patient with acromegaly.

Authors:  B Kopff; S Mucha; B H Wolffenbuttel; J Drzewoski
Journal:  Med Sci Monit       Date:  2001 Jan-Feb

6.  Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance.

Authors:  C C Szeto; K Y Li; G T Ko; C C Chow; V T Yeung; J C Chan; C S Cockram
Journal:  Int J Clin Pract       Date:  1997-10       Impact factor: 2.503

7.  Acromegaly presenting with diabetic ketoacidosis.

Authors:  J R Katz; R Edwards; M Khan; G S Conway
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

8.  Short-term cardiovascular effects of somatostatin in patients with cirrhosis.

Authors:  C Gaudin; R Moreau; B Champigneulle; O Soubrane; G Kleber; D Lebrec
Journal:  Liver       Date:  1995-10

9.  Somatostatin in the human heart and comparison with guinea pig and rat heart.

Authors:  S M Day; J Gu; J M Polak; S R Bloom
Journal:  Br Heart J       Date:  1985-02

Review 10.  Octreotide, a new somatostatin analogue.

Authors:  M D Katz; B L Erstad
Journal:  Clin Pharm       Date:  1989-04
View more
  7 in total

Review 1.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

Review 2.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

3.  Undetected pituitary adenoma in a patient with retinitis pigmentosa.

Authors:  Mousa Taghipour; Nima Derakhshan; Arash Saffarian; Meisam Ghanbari
Journal:  Chin Neurosurg J       Date:  2019-08-13

4.  Diabetes Mellitus of Pituitary Origin: A Case Report.

Authors:  Mandeep Singla; Jaspreet Kaur Saini
Journal:  touchREV Endocrinol       Date:  2021-04-28

5.  Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy.

Authors:  E. Nazlı Gönç; Alev Özön; Ayfer Alikaşifoğlu; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-06-07

Review 6.  Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review.

Authors:  Maryam Heidarpour; Davood Shafie; Ashraf Aminorroaya; Nizal Sarrafzadegan; Ziba Farajzadegan; Rasool Nouri; Arash Najimi; Christina Dimopolou; Gunter Stalla
Journal:  J Res Med Sci       Date:  2019-04-26       Impact factor: 1.852

7.  A consensus on the diagnosis and treatment of acromegaly complications.

Authors:  S Melmed; F F Casanueva; A Klibanski; M D Bronstein; P Chanson; S W Lamberts; C J Strasburger; J A H Wass; A Giustina
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.